Transcript of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2025
Awaiting price reaction for this filing.
Piramal Pharma has filed the transcript of its conference call held on 15th May 2025, where management discussed the audited standalone and consolidated financial results for the quarter and year ended 31st March 2025. This is filed under SEBI's Regulation 30(6) following the earlier intimation dated 29th April 2025. The transcript itself is hosted on the company's website and has not been reproduced in this filing. No specific financial numbers, guidance, or strategic commentary are included in this particular document.
This is a routine regulatory disclosure announcing the availability of the earnings call transcript rather than fresh information, so it is unlikely to move the stock on its own. Investors should review the full transcript on the company's website for any management guidance on margins, growth, or capital allocation that could shape near-term sentiment.